百令胶囊联合非布司他治疗尿酸性肾病临床研究

Clinical Study on Bailing Capsules Combined with Febuxostat for Uric Acid Nephropathy

目的:观察百令胶囊联合非布司他治疗尿酸性肾病的临床疗效及其对患者血清炎症因子水平的影响。方法:选择68例尿酸性肾病患者为研究对象,按照随机数字表法分为非布司他组和百令胶囊组各34例。其中非布司他组单纯予以西药非布司他治疗,百令胶囊组在非布司他组基础上联合百令胶囊治疗。2组均治疗2个月。比较2组临床疗效和不良反应,比较2组治疗前后肾功能指标及血清炎症因子水平变化。结果:百令胶囊组总有效率94.12%,高于非布司他组76.47%(P<0.05)。治疗前,2组血清尿素氮(BUN)、肌酐(SCr)、尿酸(UA)水平比较,差异无统计学意义(P>0.05);治疗后,2组血清UA、BUN、SCr水平均下降(P<0.05),且百令胶囊组低于非布司他组(P<0.05)。治疗前,2组血清C-反应蛋白(CRP)、白细胞介素-6 (IL-6)、肿瘤坏死因子-α (TNF-α)水平比较,差异无统计学意义(P>0.05);治疗后,2组血清CRP、IL-6、TNF-α水平均下降(P<0.05),且百令胶囊组低于非布司他组(P<0.05)。治疗前,2组中医证候积分比较,差异无统计学意义(P>0.05);治疗后,2组中医证候积分均降低(P<0.05),且百令胶囊组低于非布司他组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:百令胶囊联合非布司他治疗尿酸性肾病能够提高临床疗效,保护患者的肾功能,降低血清炎症因子水平,且无不良反应增加,其作用机制与抑制体内炎症反应相关。

Objective:To observe the clinical effect of the therapy of Bailing Capsules combined with Febuxostat on uric acid nephropathy and its influence on serum inflammation.Methods:A total of 68 patients with uric acid nephropathy were selected and divided into the Febuxostat group and the Bailing Capsules group according to random number table method,with 34 cases in each group.The Febuxostat group was treated with Febuxostat alone,and the Bailing Capsules group was additionally treated with Bailing Capsules based on the treatment of the Febuxostat group.Both groups were treated for two months.The clinical effects and adverse reactions in the two groups were compared,and the changes of kidney function indexes and serum inflammatory factors were compared before and after treatment.Results:The total effective rate was 94.12%in the Bailing Capsules group,higher than that of 76.47%in the Febuxostat group(P<0.05).Before treatment,there was no significant difference in the comparison of the levels of blood urea nitrogen(BUN),serum creatinine(SCr)and uric acid(UA)between the two groups(P>0.05);after treatment,the levels of UA,BUN and SCr in the two groups were decreased(P<0.05),and the above levels in the Bailing Capsules group were lower than those in the Febuxostat group(P<0.05).Before treatment,there was no significant difference in the comparison of the levels of serum C-reactive protein(CRP),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)between the two groups(P>0.05);after treatment,the levels of CRP,IL-6 and TNF-αin the two groups were decreased(P<0.05),and the above levels in the Bailing Capsules group were lower than those in the Febuxostat group(P<0.05).Before treatment,there was no significant difference in the comparison of the traditional Chinese medicine(TCM)syndrome scores between the two groups(P>0.05);after treatment,the TCM syndrome scores in both groups were decreased(P<0.05),and the scores in the Bailing Capsules group were lower than those in the Febuxostat group(P<0.05).There was no significant difference in the comparison of the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The therapy of Bailing Capsules combined with Febuxostat can improve the clinical effect on uric acid nephropathy,which can protect the kidney function of patients and reduce the levels of serum inflammatory factors without increasing adverse reactions,whose mechanism is related to the inhibition of inflammation in vivo.